EQT agrees to buy Qiagen: Oddo cuts EQT stock target to SEK 370
Published on 10/22/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTakeover and target changes
- EQT agreed to offer EUR 46.50 per Qiagen share on October 21, 2026.
- Q3 total assets under management reached EUR 354 billion versus EUR 267 billion a year earlier.
- EQT stock trades at EUR 26.23 at 9:33 a.m. CEST at Lang & Schwarz on October 22, 2026.
- Oddo cut its EQT target to SEK 370 from SEK 388 on October 20, 2026.
EQT (ISIN SE0012853455) agreed to acquire Qiagen for EUR 9.60 billion on October 21, 2026, while EQT stock traded at EUR 26.23 at Lang & Schwarz on October 22, 2026 at 9:33 a.m. CEST. Reuters reported that the offer values each Qiagen share at EUR 46.50, with completion expected in mid-2027. MarketScreener reported on October 20, 2026 that Oddo cut its EQT target from SEK 388 to SEK 370 and maintained an Outperform rating.
Qiagen adds a major strategic test
The Qiagen agreement expands EQT's healthcare and life-sciences exposure through a company serving research and clinical laboratories. Reuters reported that EQT secured equity and debt financing and that the deal includes participation from affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board.
The offer also carries execution conditions. The transaction requires regulatory clearances and is expected to close in mid-2027, so the headline value does not yet represent completed ownership.
What does the fundraising add?
EQT's own Q3 announcement dated October 15, 2026 showed total assets under management of EUR 354 billion, up from EUR 267 billion in the comparable prior-year period. Fee-generating assets under management reached EUR 195 billion versus EUR 139 billion, while gross inflows amounted to EUR 41.6 billion. EQT said the figures included EUR 34 billion from the Coller Capital combination, which closed on August 31, 2026.
Three recent EQT milestones
On July 17, 2026, EQT published its half-year report with EUR 195 billion in fee-generating assets under management. On October 15, 2026, it signed the Stockbridge agreement, including a USD 375 million cash consideration and up to USD 175 million in earnouts. On October 21, 2026, the Qiagen offer set a EUR 46.50 cash consideration per share.
Dates shaping the next phase
The next substantiated corporate date is November 30, 2026, the ex-dividend date listed for EQT. The Qiagen transaction is expected to close in mid-2027, subject to conditions.
Stock price and transaction risk
The current deal increases EQT's acquisition exposure while the company continues to scale fee-generating assets. The offer's mid-2027 closing timetable leaves regulatory approval and financing execution as material milestones for the transaction.
EQT stock was trading at EUR 26.23 at Lang & Schwarz on October 22, 2026 at 9:33 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of EQT stock.
EQT stock facts
- Company: EQT AB (publ)
- ISIN: SE0012853455
- Ticker: EQT
- Primary exchange: Nasdaq Stockholm
- Price Lang & Schwarz (as of October 22, 2026, 9:33 a.m. CEST): EUR 26.23
- Market capitalization: SEK 363.7 billion (as of October 22, 2026)
- Sector / Industry: Financial Services / Investment Management and Fund Operators
Market context: Market report OMXS30.
